Upcoming Webinar: Forging Patient Connections: How Evidence-Based Technologies Are Expanding Access and Adherence
Join us on Thursday, 10/21 @ 1:00 PM ET for this engaging webinar with PQA Quality Forum, featuring PRECISIONvalue’s Maureen Hennessey.
Digital Pharma East
Are you attending Digital Pharma East this year? Whether you’re virtual or in-person, don’t miss Precision’s Jon Bambalas chairing the Data and Analytics Track, Thursday 9/30 from 9:30am-12:50pm ET, and speaking as a panelist for the presentation: Accelerate the Value of Data: Explore Different Models for Collecting and Operationalizing Data starting at 12:10pm ET.
Impact of NextGen Access Decision Makers on Health Care Services and Therapies
In the midst of the pandemic uncertainties, organizations are continuing their quest for value-based care. Precision’s Elizabeth Oyekan and Dominic Galante discuss who will be the next generation access decision makers to successfully take the Triple Aim premise of value-based care, couple it with lessons learned from the pandemic, scale it up, and sustain success over time to make a palpable difference in the US healthcare system.
On-Demand Webinar: How to speed up patient access to innovation: Strategies to convert early European regulatory approval into optimal reimbursement
In Europe, Conditional Marketing Authorisation (CMA) offers an earlier regulatory nod from the European Medicines Agency (EMA) with lower data requirements than full approval, and with it, the opportunity for gaining earlier patient access. But Health Technology Assessment (HTA) bodies have scrutinized subsequent national-level evidence submissions and have often awarded sub-optimal reimbursement outcomes. This results in inequalities in patient access and impacts the incentives for manufacturers to continue to innovate. So what to do?
Webinar: Pricing Strategies for Advanced Therapies
There is no doubt that the advanced therapies sector is growing at an exponential rate. According to a recently published 2021 Report by ARM (Alliance for Regenerative Medicine), the sector has raised $14.1B in financing in the first half of 2021 which is already 71% of what was raised in all of 2020. In addition, there are over 2,600 advance therapy clinical trials being conducted with 264 of those trails being Phase 3 trials and another 1,500 being Phase 2 trials.
Cutting Edge Conversations: Value, Access and Evidence – Biotech Market Access
Don’t miss PRECISIONheor’s Sajjad Raza in this upcoming webinar Tuesday, September 21 at 8:00 AM PDT | 11:00 AM EDT. Hosted by Scientist.com and HealthEconomics.com as part of their Cutting Edge Conversations series, this event will be moderated by editor-in-chief Patti Peeples.
On-Demand Panel: CAR-TCR Summit, 2021
The promise of cell-based immunotherapy is giving hope to patients around the globe living with devastating disease; but the future of the cell therapy industry is still unclear. This panel discussion co-hosted by Precision for Medicine and Precision ADVANCE will feature key insights and discussion from advanced therapy leaders on the pros and cons of developing Autologous and Allogeneic cell therapies.
AMCP & Precision ADVANCE Corporate Training Program
Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies. These differences will impact how innovators develop evidence and manufacture and distribute products. Payers also need to adapt how they assess value, make coverage decisions, and manage reimbursement.
The Complementary Relationship Between Quantitative and Qualitative Research Methods in Enhancing Understanding of Treatment Decisions, Outcomes, and Value Assessment
Quantitative studies are the gold standard for establishing causality and drawing conclusions that can be generalized beyond the population studied. However, quantitative research methods also often lack contextual considerations and perspectives that can be further informed by qualitative approaches.
